Crystagen
- Category
- Bioregulators
- Administration routes
- Oral
- Regulatory status
- Not FDA-approved
Crystagen is a synthetic tripeptide (Glu-Asp-Pro) marketed to normalize immune function, boost stress resistance, and support thymus activity during aging. The case is mechanism only: effects on T-cell gene expression are unconfirmed in humans, so claimed benefits remain speculative. Independent safety data are limited, with a theoretical risk of worsening autoimmune conditions. It is not FDA-approved and circulates as unregulated research-grade product.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Crystagen is a synthetic peptide bioregulator belonging to the Cytogens class, developed by Prof. Vladimir Khavinson's team at the St. Petersburg Institute of Bioregulation and Gerontology. Unlike the natural Cytomaxes (extracted from animal tissue), Cytogens like Crystagen are synthesized from amino acids to replicate the activity of thymus-derived peptides. Crystagen specifically targets the immune system, where it is designed to normalize thymus function and support immune cell differentiation and activity.
The thymus gland plays a critical role in T-cell maturation and immune regulation, but undergoes significant involution (shrinkage) with age, contributing to immunosenescence. Crystagen is positioned as a synthetic alternative to Vladonix (the natural thymus peptide bioregulator) and is related to the well-studied thymus peptide drug Thymalin. Research by Khavinson et al. investigates EDP (Crystagen) and KE (Vilon) as distinct peptides with proposed immune effects; KE is not a component of the EDP tripeptide.
A PMC-indexed paper (PMC8365293) describes Crystagen given with other short peptides to increase stress resistance and normalize immunity in athletes. However, independent Western clinical trials are lacking, and evidence remains primarily from Russian research groups.
How it works in the body
A synthetic tripeptide (Glu-Asp-Pro) investigated for immune effects. Nuclear DNA binding is a proposed mechanism supported partly by modeling; restoration of immune function in humans is not established.
Research overview
Crystagen is part of the broader Khavinson peptide bioregulator research program that spans over 40 years. A PMC-indexed review (PMC8365293) on thymalin and its molecular components describes how the dipeptide KE (Vilon) and tripeptide EDP (Crystagen) regulate gene expression, heat-shock protein synthesis, cytokine production, fibrinolysis, and cell differentiation, proliferation, and apoptosis. The oral administration of Crystagen in combination with other short peptides has been shown to increase stress resistance and normalize immunity in athletes. The broader thymus peptide research (thymalin, thymogen) provides the scientific framework for Crystagen, with studies showing immunocorrective properties in immunodeficiency, infection, and post-radiation states. However, Crystagen itself has not been studied in independent Western clinical trials.
Who researches Crystagen?
Commonly researched by
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(2)
Rated by level of concern
Limited independent safety data
HighClinicalTrials.gov API (0 records); PubMed (single non-clinical record, no safety/toxicology publication for crystagen); no FDA approval or DailyMed listing
Potential immune modulation in autoimmune conditions
TheoreticalPMID 28976144 (B-cell activation, ex vivo spleen culture); no clinical adverse-event reports identified
Interaction summary(8)
Rated by direction with this peptide
Calcineurin inhibitors and antimetabolite immunosuppressants (tacrolimus, cyclosporine, mycophenolate, azathioprine)
CautionTheoreticalAn agent marketed for lymphocyte activation works directionally against maintenance immunosuppression, so transplant or severe-autoimmune patients risk undermining a therapy where loss of control is high-consequence — though no interaction study or case report exists.
Mechanism-based extrapolation from the B-cell activation reported in PMID 28976144. No published interaction data.
Systemic corticosteroids
CautionTheoreticalCorticosteroids are lymphotoxic and broadly immunosuppressive, so effects would be expected to oppose one another, with the practical concern being a patient reducing prescribed steroids on the assumption the peptide compensates.
Mechanism-based; no interaction studies for crystagen
Biologic DMARDs (TNF inhibitors, IL-6/IL-17 blockers, rituximab)
CautionTheoreticalIn autoimmune disease these drugs deliberately suppress the lymphocyte and cytokine activity Crystagen is claimed to stimulate, and the B-cell activation signal is a specific concern alongside B-cell-depleting therapy such as rituximab.
Mechanism-based; B-cell activation reported ex vivo in PMID 28976144. No clinical data.
Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab)
CautionTheoreticalUsing an unvalidated immune stimulant with agents whose dose-limiting toxicity is immune-related adverse events adds unquantified risk of colitis, hepatitis, or pneumonitis with no offsetting evidence of benefit.
Mechanism-based; no published data on crystagen with checkpoint inhibitors
Cytotoxic chemotherapy (myelosuppressive regimens)
CautionTheoreticalOther Russian thymic preparations (Thymalin, Thymogen) were historically used to blunt chemotherapy-associated immunosuppression, but that evidence belongs to those preparations and does not transfer: Crystagen has no oncology, myelosuppression, or co-administration data of any kind, so adding it during chemotherapy is unstudied rather than supportive.
Class-level rationale only (Thymalin/Thymogen literature, not verified as transferable); no crystagen-specific studies
Other Khavinson short-peptide bioregulators (Thymogen, Vilon, Thymalin)
NeutralTheoreticalThese peptides are studied side by side in the same immunoprotective models, but the single comparative study showed distinct, non-overlapping effects — no additive or potentiating benefit has been demonstrated, and no combined-exposure safety data exists.
PMID 28976144 (Vilon, Timogen, Crystagen and R-1 compared in aged spleen culture)
Live attenuated vaccines
CautionTheoreticalAny unpredictable shift in T- and B-cell responsiveness around live-vaccine administration is unstudied for Crystagen, so timing effects on either take or reactogenicity are simply unknown.
Mechanism-based; no vaccine co-administration data for crystagen
Antiretroviral therapy / HIV and other chronic immune-dysregulation states
CautionTheoreticalNo pharmacokinetic interaction is expected with a tripeptide, but the population is one where unvalidated immune stimulation could perturb a carefully monitored immune recovery without any evidence base to guide it.
Mechanism-based; no clinical data
Known risks(2)
Limited independent safety data
LowNo serious adverse events reported, but independent safety studies outside Russia are absent.
Potential immune modulation in autoimmune conditions
ModerateAs an immune-modulating peptide, theoretical risk exists for exacerbating autoimmune conditions. Individuals with autoimmune disorders should consult a physician before use.
Drug interactions(2)
Immunosuppressants (cyclosporine, tacrolimus, etc.)
Theoretical antagonism; immune-stimulating effects may counteract immunosuppression
Biologics for autoimmune conditions
Theoretical interaction; immune modulation may interfere with biologic therapy
Research & benefits
Evidence base
- Evidence Level
- Very Limited Evidence
- Total Studies
- 3
- Human Studies
- 50
Direct clinical evidence for Crystagen is very limited. The strongest supporting data comes from the broader thymus peptide research (thymalin, thymogen) conducted in Russia over several decades, which shows immunocorrective effects. Crystagen specifically has been used in multi-peptide regimens for athletes but lacks standalone randomized controlled trials. The PMC-indexed thymalin review provides mechanistic context but not direct Crystagen clinical evidence.
Researched for(3)
Rated by confidence in the evidence
Immune system normalization and support
SpeculativeDeveloper reports include laboratory studies and a small clinical comparison; independent clinical benefit remains unconfirmed.
PMID 28976144 (Chervyakova et al., Adv Gerontol 2014); ClinicalTrials.gov API query 'crystagen' = 0 studies (https://clinicaltrials.gov/api/v2/studies?query.term=crystagen)
Increased stress resistance in athletes
SpeculativeDeveloper reports describe combination use in athletes; they do not establish a Crystagen-specific benefit.
PubMed search 'crystagen' (https://pubmed.ncbi.nlm.nih.gov/?term=crystagen) - 1 result, non-clinical; no ClinicalTrials.gov records
Support for thymus function during aging (immunosenescence)
SpeculativeDeveloper patent experiments include thymus models; clinical thymus rejuvenation remains unproven.
PMID 28976144; class-level chromatin data PMID 23221144, PMID 33526740, PMID 37042594 (all Georgian Med News, all testing peptides other than Crystagen)
Benefits(3)
Immune system normalization and support
PMC8365293 (thymalin review); Khavinson Institute protocols
Increased stress resistance in athletes
PMC8365293; multi-bioregulator athlete study (Crystagen + Pinealon + Vesugen + others)
Support for thymus function during aging (immunosenescence)
Khavinson peptide bioregulator research program; thymalin clinical data extrapolation
Key studies(2)
The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity
ReviewN/A (review)Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM
Biology Bulletin Reviews
2021
Comprehensive review of thymalin and its component peptides (including those in Crystagen). Shows that short thymus peptides regulate gene expression, cytokine synthesis, and cell differentiation. Oral Crystagen in combination with other peptides normalized immunity in athletes.
Short peptides regulate gene expression
Computational molecular dockingKhavinson VKh, Linkova NS, Tarnovskaya SI
Bulletin of Experimental Biology and Medicine
2016
Docking models predicted binding of KE and EDP peptides to the AGAT DNA sequence; this does not demonstrate gene regulation in patients.
Regulation & availability
Why researchers look at it
Crystagen is a synthetic thymus-targeting peptide designed to support immune function during aging. As part of the Khavinson Cytogens class, it offers a non-animal-derived approach to immune bioregulation, though clinical evidence remains limited to Russian studies.
- Estimated cost
- $30-60/mo (capsules)
- FDA status
- Not FDA-approved; not reviewed by FDA; sold as dietary supplement internationally
- WADA status
- Not individually named in the 2026 List. S0 prohibits at all times pharmacological substances not covered by later sections that lack current approval by any governmental health authority for human therapeutic use. Crystagen's substance-specific anti-doping status requires confirmation.
- Prescribability
- Available in Russia as dietary supplement; not approved in USA/EU
- Availability
- Sold as a synthesized peptide dietary supplement. More readily available than natural Cytomaxes due to synthetic production. Not available through conventional pharmacies in the USA or EU.
International status
EU
Not approved
US
Not approved
Russia
Used clinically (Khavinson bioregulator protocol)
Worldwide
Limited to Russian clinical use
Regulatory timeline(2)
- 2000sDeveloped as synthetic Cytogen at St. Petersburg Institute of Bioregulation and Gerontology
- 2010sCommercialized as dietary supplement
Sources & FAQs
Research sources(2)
Frequently asked questions(3)
How is Crystagen different from Vladonix?
Crystagen is a synthetic peptide (Cytogen class) while Vladonix is a natural extract (Cytomaxes class). Both target the thymus/immune system, but Crystagen is synthesized from amino acids rather than extracted from animal thymus tissue. They are considered complementary in Khavinson's bioregulator system.
What peptide is Crystagen?
Crystagen is EDP (Glu-Asp-Pro). KE (Lys-Glu) is Vilon, a different peptide.
Is Crystagen safe?
As a synthetic peptide, Crystagen avoids the prion/allergen concerns of animal-derived products. Khavinson's group reports no serious side effects across decades of use, but independent safety studies are absent. No major adverse events reported in literature.